Trinity Biotech PLC (TRIB) stock
TRIBNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$6.01+0.63 (+11.81%)
Close on Nov 17, 2026Market cap $112.45MP/E –Yield –
Trinity Biotech r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $3.63M, down 20.1% from the year before. Over ten years it grew -3.3% a year on average. The highest annual figure on record is $5.66M in fiscal 2017.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.63M | -20.1% |
| FY2024 | Dec 31, 2024 | $4.54M | +3.7% |
| FY2023 | Dec 31, 2023 | $4.38M | +5.8% |
| FY2022 | Dec 31, 2022 | $4.14M | -8.0% |
| FY2021 | Dec 31, 2021 | $4.50M | -11.5% |
| FY2020 | Dec 31, 2020 | $5.08M | -4.6% |
| FY2019 | Dec 31, 2019 | $5.33M | -0.8% |
| FY2018 | Dec 31, 2018 | $5.37M | -5.1% |
| FY2017 | Dec 31, 2017 | $5.66M | +12.2% |
| FY2016 | Dec 31, 2016 | $5.04M | -0.6% |
| FY2015 | Dec 31, 2015 | $5.07M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2018 | Jun 30, 2018 | $1.42M | – |
| Q2 FY2017 | Jun 30, 2017 | $1.32M | – |
See a number that looks wrong?